Skip to main content
Testing version — LOERadar is in active testing. Features and data may change.
LOERadar
LOE
Radar
Intelligence Hub
News
Changes
Search
Log in
Get Started
FABHALTA (IPTACOPAN HYDROCHLORIDE) | LOERadar
Viewing data from:
Latest
2026-07-01
2026-06-01
2026-05-01
2026-04-01
2026-03-28
2026-02-17
2026-02-10
2025-12-14
2025-02-26
2025-01-25
2024-11-08
2023-07-23
2023-06-15
2023-05-13
2023-01-26
2022-11-22
2022-10-28
2022-09-29
2022-07-09
2022-06-29
2022-04-08
2022-03-09
2021-12-28
2021-05-05
2021-03-12
2020-12-22
2020-11-12
2019-12-14
2019-09-15
FABHALTA
NDA
IPTACOPAN HYDROCHLORIDE | N218276 | NOVARTIS PHARMACEUTICALS CORP
1 strength
8 unique patents
5 unique exclusivities
Patents
SEC Intel
Revenue
PTAB
Reexams
Litigation
Petitions
Trials
Price Trends
VA FSS
Medicare D
Approvals
Label
Products
Patent Timeline
8 unique patents, 5 exclusivities by expiration date
Active (8)
Today
Exclusivity
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
Today
9682968
Jul. 14, 2034
10093663
Jul. 14, 2034
11603363
May. 25, 2041
11723901
Aug. 30, 2038
11951101
Jul. 15, 2041
12285422
Aug. 30, 2038
12384758
May. 17, 2041
12453726
Jul. 15, 2041
I-949
Aug. 7, 2027
I-963
Mar. 20, 2028
NCE
Dec. 5, 2028
ODE-456
Dec. 5, 2030
ODE-524
Mar. 20, 2032
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
No ANDA patent litigation cases (NOS 835) matched from PACER
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (1)
#001 — EQ 200MG BASE
RLD
8 patents
5 exclusivities
▴
CAPSULE;ORAL | Approved: Dec 5, 2023
Patents (8)
· 8 use codes
Patent #
Expiration
PED
Drug Substance
Drug Product
Use Code
Delist
9682968
Jul 14, 2034
—
Yes
Yes
—
—
10093663
Jul 14, 2034
—
—
—
U-3980
TREATMENT OF PRIMARY IMMUNOGLOBULIN A NEPHROPATHY (IGAN)
U-4161
TREATMENT OF COMPLEMENT 3 GLOMERULOPATHY (C3G)
—
11603363
May 25, 2041
—
Yes
Yes
—
—
11723901
Aug 30, 2038
—
—
—
U-3980
TREATMENT OF PRIMARY IMMUNOGLOBULIN A NEPHROPATHY (IGAN)
—
11951101
Jul 15, 2041
—
—
—
U-3895
TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) BY ADMINISTRATION OF 200 MG OF IPTACOPAN TWICE DAILY
—
12285422
Aug 30, 2038
—
—
—
U-4181
TREATMENT OF COMPLEMENT 3 GLOMERULOPATHY (C3G) BY ADMINISTRATION OF 200 MG OF IPTACOPAN TWICE DAILY
—
12384758
May 17, 2041
—
—
—
U-3980
TREATMENT OF PRIMARY IMMUNOGLOBULIN A NEPHROPATHY (IGAN)
U-4161
TREATMENT OF COMPLEMENT 3 GLOMERULOPATHY (C3G)
—
12453726
Jul 15, 2041
—
—
—
U-4300
TREATMENT OF PAROXYSMAL NOCTURAL HEMOGLOBINURIA (PNH) BY ADMINISTRATION OF 200 MG OF IPTACOPAN TWICE DAILY
—
Exclusivities (5)
Code
Date
Status
I-949
Aug 7, 2027
Active
I-963
Mar 20, 2028
Active
NCE
Dec 5, 2028
Active
ODE-456
Dec 5, 2030
Active
ODE-524
Mar 20, 2032
Active